Every intervention Outliyr has scored for blood sugar control, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for blood sugar control; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
65 of 104 evaluated interventions score 3.0+ out of 10 for blood sugar control · 16 comparisons
Semaglutide earns 9.5/10 for blood-sugar because Buse 2025 found higher HbA1c target achievement than alternative treatment in type 2 diabetes. This is the cleanest use case: GLP-1 receptor signaling increases glucose-dependent insulin…
Read the Semaglutide report →Tirzepatide improves blood-sugar control, achieving average HbA1c reductions of about 1.5 % in phase 3 trials of type 2 diabetes patients Frias 2021. Tirzepatide's dual GIP and GLP-1 receptor agonism drives stronger…
Read the Tirzepatide report →Metformin earns a 9.0/10 score for the blood-sugar use case, reflecting the UKPDS 34 trial's 35% reduction in diabetes-related endpoints versus standard care UK Prospective Diabetes Study Group 1998. Metformin also slowed…
Read the Metformin report →For readers prioritizing blood sugar, Berberine scores 8.2/10 today. Yin 2008 showed berberine improved glycemic markers in type 2 diabetes, and Lan 2015 supports glucose-lowering direction across randomized trials. This is the…
Read the Berberine report →The blood-sugar case for Retatrutide is 8.0/10 because Sanyal 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: this verified source reported HbA1c reductions up to…
Read the Retatrutide report →Magnesium blood sugar earns 7.6/10 because Asbaghi 2022 anchors the most relevant signal. Magnesium fits blood sugar when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible.…
Read the Magnesium report →The practical blood-sugar read on Zone 2 Cardio is 7.5/10 because Lang 2024 anchors the strongest signal. The existing rationale points to this narrower claim: Zone 2 improves glucose disposal through muscle…
Read the Zone 2 Cardio report →Taurine looks most relevant to blood-sugar control at 7.5/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Systematic 2022…
Read the Taurine report →Mechanistically, Time-Restricted Eating scores 7.4/10 for blood sugar because the evidence points to a plausible use case without proving a universal response. Dai W et al. 2024 is the best anchor here…
Read the Time-Restricted Eating report →Glycemic control scores 7.0/10. Polyphenol-rich foods consistently associate with lower type 2 diabetes risk in cohorts, with flavonoids around HR 0.88 and flavan-3-ols near HR 0.89 per pooled prospective data, and a…
Read the Polyphenols (Dietary) report →Blood sugar scores 7.0/10 on the strength of glycemic meta-analyses. Hatami 2021 pooled 8 studies in type 2 diabetes and found fasting glucose dropping 17.88 mg/dL, although HbA1c did not move significantly.…
Read the Spirulina report →Blood-sugar control earns 7.0/10 because SIT directly improves insulin action. Babraj 2009 cut glucose area-under-curve 12 percent and insulin area-under-curve 37 percent after just six sessions, and Metcalfe 2012 raised insulin sensitivity…
Read the Sprinting (Sprint Interval Training) report →Mechanistically, Ketogenic Diet scores 7.0/10 for blood sugar because the evidence points to a plausible use case without proving a universal response. Eshaghhosseiny Z et al. 2024 is the best anchor here…
Read the Ketogenic Diet report →Glycemic control earns 6.5/10 on the back of the single largest effect in the literature. Kumar 2023 reported HOMA-IR insulin resistance fell 64 percent over 16 weeks in older adults, and the…
Read the GlyNAC (Glycine + N-Acetylcysteine) report →Glycine blood sugar earns 6.2/10 because Soh 2024 anchors the most relevant signal. Glycine fits blood sugar because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →Blood-sugar support earns Norwegian 4x4 a 6.0/10 because high-intensity interval training can improve glucose regulation in metabolic-syndrome cohorts Poon 2024. The protocol uses repeated near-maximal aerobic efforts that increase muscle glucose uptake…
Read the Norwegian 4×4 report →A 6.0/10 blood sugar rating fits Blood-Flow Restriction Training, since Zhang et al. 2025 points to a real but bounded effect. Low-load exercise with BFR can increase skeletal-muscle glucose uptake indirectly; evidence…
Read the Blood-Flow Restriction Training report →For glycemic control vitamin C scores 6.0/10, driven by the Ashor 2017 systematic review and meta-analysis of randomized trials, which found significant reductions in HbA1c and fasting glucose concentrated in people with…
Read the Vitamin C (Ascorbic Acid) report →The evidence supports a modest glycemic benefit from Whole-Body Vibration, with a meta-analysis reporting a small but significant reduction in fasting glucose for type 2 diabetes patients (Fabregat-Fernandez 2024). Whole-Body Vibration use…
Read the Whole-Body Vibration report →MOTS-c gets 6.0/10 for blood sugar; the evidence supports a narrow read. MOTS-c blood-sugar support comes from AMPK-mediated glucose disposal and mouse insulin-sensitivity findings in Lee 2015. Human data remains biomarker-observational, not…
Read the MOTS-c report →Blood sugar control is well supported even though the diabetes indication is still pending. In early type 2 diabetes the 36 mg dose lowered HbA1c about 1.48 percent versus 0.41 percent on…
Read the Orforglipron (Foundayo) report →Blood sugar control is a clear strength in the diabetic population. REDEFINE 2 reported that 74% of people with type 2 diabetes reached an HbA1c at or below 6.5%, a target that…
Read the CagriSema (Cagrilintide + Semaglutide) report →Blood sugar is the most practically tracked sulforaphane endpoint. Axelsson 2017 and Dwibedi 2025 together support a fasting glucose effect in dysregulated subgroups, with Dwibedi 2025 showing a responder subgroup reduction around…
Read the Sulforaphane report →Glucose control is genuinely strong despite the glucagon leg's tendency to raise blood sugar. In the Phase 2 diabetes trial, HbA1c fell about 1.67 percent on 6 mg and 73.5 percent of…
Read the Mazdutide (IBI362) report →The blood-sugar control case for Astaxanthin is 5.5/10 because Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Maleki-Hajiagha…
Read the Astaxanthin report →TUDCA scores 5.5/10 for blood sugar because the best human anchor is insulin sensitivity, not direct HbA1c or remission data. Kars 2010 found improved hepatic and skeletal-muscle insulin sensitivity after four weeks…
Read the TUDCA (Tauroursodeoxycholic Acid) report →A 5.5/10 for blood-sugar fits Methylene Blue because Rodriguez 2016 supports direction more than certainty. The existing rationale points to this narrower claim: Blood-sugar support remains theoretical and community-driven. Methylene blue's redox…
Read the Methylene Blue report →A ketone ester acutely lowers blood glucose. Myette-Cote 2018 reported a roughly 17 percent reduction in glucose area-under-curve after an oral glucose tolerance test in 20 healthy adults when ketones were taken…
Read the Exogenous Ketones report →For blood-sugar control, TRT (Testosterone Replacement Therapy) scores 5.5/10 because Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with monitoring-relevant safety signals.…
Read the TRT (Testosterone Replacement Therapy) report →The evidence for SLU-PP-332's blood-sugar use case scores 5.5 / 10, based on mouse obesity data showing improved glucose handling with a synthetic ERR agonist Billon 2024. SLU-PP-332 aims to boost fatty-acid…
Read the SLU-PP-332 report →Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.2/10 for blood-sugar because Demidenko 2021 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct human glucose RCTs. Keep…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Blood-sugar control is solid but not the headline. In a 16-week type 2 diabetes trial, survodutide up to 2.7 mg per week matched semaglutide 1.0 mg on HbA1c reduction while delivering more…
Read the Survodutide (BI 456906) report →Grass-Fed Whey Protein scores 5.0/10 for blood sugar because human insulin-sensitivity work gives a modest metabolic signal. The strongest support comes from Shimomura Y. et al. 2006, but the practical rating stays…
Read the Grass-Fed Whey Protein report →Vitamin D3 + K2 blood sugar earns 5.0/10 because Pittas 2019 anchors the most relevant signal. Vitamin D3 + K2 fits blood sugar when deficiency, bone risk, immune seasonality, or fat-soluble nutrient…
Read the Vitamin D3 + K2 report →Rapamycin blood sugar earns 5.0/10 because Lamming 2012 anchors the most relevant signal. Rapamycin fits blood sugar when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score…
Read the Rapamycin report →Blood-sugar control earns 5.0/10 because the fasting-glucose reduction in Fallah 2018 was small (4.23 mg/dL, P=0.041) and rests on fewer trials than the lipid endpoints, with no strong HbA1c or insulin-sensitivity outcome…
Read the Chlorella report →Curcumin's glucose-lowering effect is one of its more repeatable metabolic actions. The same 2018 metabolic syndrome meta-analysis found reductions in fasting glucose, HbA1c, and insulin resistance. Effect sizes are small-to-moderate and vary…
Read the Curcumin report →NMN blood sugar earns 5.0/10 because Yoshino 2021 anchors the most relevant signal. NMN fits blood sugar when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The…
Read the NMN (Nicotinamide Mononucleotide) report →Blood-sugar control scores 5.0/10 because the insulin-sensitivity signal is real but glucose itself rarely moves. In Ham 2024 (75 adults, 12 weeks, 350 mg magnesium) HOMA-IR and fasting insulin both fell, yet…
Read the Quinton Marine Plasma (Seawater Minerals) report →Blood sugar control is a direct, mechanistically expected benefit of the dual-incretin design, and the early data backs it. The VENTURE Phase 2 injectable trial saw about 78 percent of prediabetic participants…
Read the VK2735 (Viking Therapeutics) report →Blood-sugar score stays cautious because amino acid metabolites correlate with insulin resistance and future glucose dysregulation in cohorts. This is not proof that EAA supplements cause diabetes.
Read the Essential Amino Acids report →Blood sugar control is a genuine but secondary benefit. Amylin slows gastric emptying and suppresses glucagon after meals, which blunts glucose spikes, and unlike insulin secretagogues it carries minimal hypoglycemia risk, per…
Read the Cagrilintide (AM833) report →Blood-sugar support is modest: Zhang 2025 found fasting glucose and HbA1c improvements across cardiometabolic RCTs, but publication-bias and endpoint heterogeneity keep the score mid-range.
Read the Saffron report →Blood-sugar effects are more credible in diabetes or impaired-glucose-tolerance populations than in healthy users. A Cochrane review for adults with type 2 diabetes found very-low-certainty evidence and too little long-term patient-relevant data…
Read the Resveratrol report →Glycemic data for traditional sauna is thin. Heat stress can transiently improve insulin sensitivity in small studies, but there is no large outcome cohort for blood sugar specifically, so this stays mechanistic…
Read the Traditional Sauna (Finnish Dry-Heat) report →Glycemic control is a modest 4.0/10. A few meta-analyses report small reductions in fasting glucose or HbA1c in diabetics, but the effect is inconsistent and minor relative to diet, exercise, or medication.…
Read the Coenzyme Q10 (CoQ10 / Ubiquinol) report →Endothelial protection from hyperglycemia is described mechanistically, but no human glycemic-control trial supports a direct blood-sugar benefit.
Read the Ergothioneine report →Robinson 2024 (Robinson 2024) was null on fasting glucose, fasting insulin, and HOMA-IR over 12 weeks at 200 mg/day. Wang 2024 (Wang 2024) adds a preclinical pregnancy caution because maternal pentadecanoic-acid feeding…
Read the C15 (Pentadecanoic Acid) report →HBOT may shift glucose during treatment in patients with diabetes, making monitoring important. McIntosh 2021 reviews intra-session glycemic effects. Evidence does not support using hyperbaric oxygen as primary glycemic control. The practical…
Read the Hyperbaric Oxygen Therapy report →Glycemic effects are inconsistent and mostly appear in combination protocols or in already-healthy people, not in isolation for people with poor glucose control. Treat any blood-sugar benefit as unproven for the typical…
Read the Sodium Butyrate report →Contracting muscle increases glucose uptake, and more muscle mass can support insulin sensitivity. Direct WB-EMS blood-sugar data remain limited, with Guretzki 2024 showing only a small composite metabolic signal.
Read the Full-Body EMS report →No direct glycemic RCT data were identified. Animal and mechanistic signals are not enough for a clinically useful blood-sugar score.
Read the Tongkat Ali report →Blood-sugar support is modest and indirect. Cortisol reduction can improve insulin sensitivity in stressed users, and v0 evidence included glucose improvements, but ashwagandha is not a diabetes treatment. Users on antidiabetic medications…
Read the Ashwagandha report →A whole-seaweed RCT showed no glucose benefit and an isolated-fucoidan trial worsened HOMA-IR; human glycemic evidence is unfavorable to neutral.
Read the Fucoidan (Brown Seaweed Polysaccharide) report →Tesamorelin can modestly worsen glucose tolerance in susceptible users despite VAT benefits. FDA labeling warns about glucose intolerance and diabetes monitoring, so blood-sugar scoring remains intentionally conservative.
Read the Tesamorelin report →Mixed to null. Klupp 2016 found no HbA1c or fasting-glucose effect from reishi; one small open-label reishi trial and animal chaga data point the other way but are low quality.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →The Arabi 2023 umbrella review found no consistent effect on FBG or HOMA-IR, although insulin levels moved in some analyses. Shi 2016 reported no change in glucose despite a 26.5 micromol per…
Read the Quercetin report →Any blood-sugar benefit is indirect, riding on the weight loss rather than a measured glycemic endpoint. Losing 9 to 11 percent of body weight reliably improves insulin sensitivity, but no tesofensine trial…
Read the Tesofensine report →Autonomic balance affects insulin sensitivity; one small study supports.
Read the HRV Biofeedback report →Magnesium participates in insulin signaling and dehydration can worsen glucose tolerance; electrolyte correction supports baseline physiology without reliably lowering glucose in replete users.
Read the Electrolytes report →Indirect via PCOS insulin-sensitivity context only. No meaningful direct glycemic-control RCT evidence in the general population.
Read the NAC (N-Acetylcysteine) report →Animal diabetes data support a weak blood-sugar hypothesis, but peer-reviewed human RCT evidence is absent. Lion's Mane should not be framed as a glucose-control supplement.
Read the Lion’s Mane report →Glycemic effects appear only in the GlyNAC precursor data, not in glutathione monotherapy, scoring 3.0/10.
Read the Glutathione (GSH) report →Dollerup 2018 was explicitly null for insulin sensitivity in obese men at 2,000 mg/day over 12 weeks, so blood-sugar support remains weak despite NAD+ pathway relevance.
Read the NR (Nicotinamide Riboside) report →Blood-sugar improvements come mainly from related NNMT inhibitors in mice (Kannt 2018), not direct 5-Amino-1MQ trials.
Read the 5-Amino-1MQ report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Tirzepatide, at 6.1, then semaglutide at 6.0, then orforglipron at 5.8 if you want the pill. All three are approved, all three have real trial evidence, and all…
Ca-AKG, urolithin A and MOTS-c tie at 6.5, and only the first two are things you can legally buy. SS-31 follows at 6.0. The bottom three score low…
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
No. Omega-3 scores 6.8 and C15:0 4.9, and the evidence gap is larger than the score gap. C15:0 has two small human trials. Omega-3 has outcome trials, prescription…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Sulforaphane scores 6.8 and glutathione 6.2, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Different liver problems. NAC scores 8.0 and TUDCA 6.7, and NAC wins liver detox 8.0 against 6.5, but its liver evidence is toxin and oxidative damage. TUDCA owns…
GHRP-2 scores 5.5 and GHRP-6 scores 5.1. Both are ghrelin-receptor peptides doing the same job, and appetite is the only difference that changes a decision. Pick GHRP-2 for…
Metformin scores 6.9 and berberine 6.8, so the gap is meaningless. Metformin owns blood sugar with decades of outcome trials behind it. Berberine owns fatty liver, needs no…
MOTS-c scores 6.5 and SS-31 6.0, and neither one has a human trial behind the use you want. MOTS-c takes blood sugar and body composition. SS-31 takes the…
NMN scores 6.3, NR 6.1, and direct NAD+ 5.0. The oral precursors win on evidence and price. NMN takes blood sugar and metabolic health. NR takes cardiovascular and…
Semaglutide, at 9.5 out of 10 for blood sugar control. Semaglutide earns 9.5/10 for blood-sugar because Buse 2025 found higher HbA1c target achievement than alternative treatment in type 2 diabetes.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 6.2 out of 10 for blood sugar control.
65 of the 104 interventions evaluated for blood sugar control score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
